JP5893738B2 - グリコシダーゼ阻害剤としてのピラノ[3,2−d][1,3]チアゾール - Google Patents
グリコシダーゼ阻害剤としてのピラノ[3,2−d][1,3]チアゾール Download PDFInfo
- Publication number
- JP5893738B2 JP5893738B2 JP2014527246A JP2014527246A JP5893738B2 JP 5893738 B2 JP5893738 B2 JP 5893738B2 JP 2014527246 A JP2014527246 A JP 2014527246A JP 2014527246 A JP2014527246 A JP 2014527246A JP 5893738 B2 JP5893738 B2 JP 5893738B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- atoms
- pyrano
- disease
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527323P | 2011-08-25 | 2011-08-25 | |
| US61/527,323 | 2011-08-25 | ||
| PCT/US2012/051785 WO2013028715A1 (en) | 2011-08-25 | 2012-08-22 | Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014527060A JP2014527060A (ja) | 2014-10-09 |
| JP2014527060A5 JP2014527060A5 (enExample) | 2015-10-29 |
| JP5893738B2 true JP5893738B2 (ja) | 2016-03-23 |
Family
ID=46759099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527246A Active JP5893738B2 (ja) | 2011-08-25 | 2012-08-22 | グリコシダーゼ阻害剤としてのピラノ[3,2−d][1,3]チアゾール |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8884023B2 (enExample) |
| EP (1) | EP2748171B1 (enExample) |
| JP (1) | JP5893738B2 (enExample) |
| KR (1) | KR102008032B1 (enExample) |
| CN (1) | CN103930428B (enExample) |
| AU (1) | AU2012298949B2 (enExample) |
| BR (1) | BR112014004219B1 (enExample) |
| CA (1) | CA2845149C (enExample) |
| DK (1) | DK2748171T3 (enExample) |
| EA (1) | EA022562B1 (enExample) |
| ES (1) | ES2568603T3 (enExample) |
| HR (1) | HRP20160334T1 (enExample) |
| HU (1) | HUE029390T2 (enExample) |
| IL (1) | IL231008A (enExample) |
| MX (1) | MX358463B (enExample) |
| PL (1) | PL2748171T3 (enExample) |
| RS (1) | RS54773B1 (enExample) |
| SG (1) | SG2014009617A (enExample) |
| SI (1) | SI2748171T1 (enExample) |
| WO (1) | WO2013028715A1 (enExample) |
| ZA (1) | ZA201400387B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201249848A (en) * | 2010-11-08 | 2012-12-16 | Merck Sharp & Dohme | Selective glycosidase inhibitors and uses thereof |
| LT2655388T (lt) | 2010-12-23 | 2016-11-10 | Alectos Therapeutics Inc. | Selektyvieji glikozidazės inhibitoriai ir jų panaudojimas |
| WO2012126091A1 (en) | 2011-03-24 | 2012-09-27 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2691407B1 (en) * | 2011-03-31 | 2017-02-22 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2013000084A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2013000086A1 (en) | 2011-06-27 | 2013-01-03 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2726468B1 (en) | 2011-06-27 | 2017-04-12 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| SG2014009617A (en) * | 2011-08-25 | 2014-05-29 | Merck Patent Gmbh | Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors |
| US9809537B2 (en) | 2012-08-31 | 2017-11-07 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| US9670195B2 (en) | 2012-08-31 | 2017-06-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| US9695197B2 (en) | 2012-10-31 | 2017-07-04 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| WO2014100934A1 (en) * | 2012-12-24 | 2014-07-03 | Merck Sharp & Dohme Corp. | Glycosidase inhibitors and uses thereof |
| KR102043337B1 (ko) | 2014-08-28 | 2019-11-11 | 아셰뉴론 에스아 | 글리코시다제 저해제 |
| EP3352540B1 (en) * | 2015-09-18 | 2021-03-17 | Toray Industries, Inc. | Housing |
| ES2879351T3 (es) | 2016-02-25 | 2021-11-22 | Asceneuron Sa | Sales de derivados de piperazina obtenidas por adición de ácidos |
| MA43680A (fr) | 2016-02-25 | 2018-11-28 | Asceneuron Sa | Inhibiteurs de glycosidases |
| US11261183B2 (en) | 2016-02-25 | 2022-03-01 | Asceneuron Sa | Sulfoximine glycosidase inhibitors |
| JP2019510006A (ja) | 2016-02-25 | 2019-04-11 | エースニューロン・ソシエテ・アノニム | グリコシダーゼ阻害剤 |
| US11213525B2 (en) | 2017-08-24 | 2022-01-04 | Asceneuron Sa | Linear glycosidase inhibitors |
| WO2020039028A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Tetrahydro-benzoazepine glycosidase inhibitors |
| WO2020039027A1 (en) | 2018-08-22 | 2020-02-27 | Asceneuron S. A. | Pyrrolidine glycosidase inhibitors |
| EA202190275A1 (ru) | 2018-08-22 | 2021-08-02 | Асенейрон С. А. | Сукцинатные и фумаратные кислотно-аддитивные соли производных пиперазина, пригодные в качестве ингибиторов гликозидазы |
| US11731972B2 (en) | 2018-08-22 | 2023-08-22 | Asceneuron Sa | Spiro compounds as glycosidase inhibitors |
| WO2021086966A1 (en) * | 2019-10-29 | 2021-05-06 | Biogen Ma Inc. | Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2436687A1 (en) * | 2005-03-01 | 2012-04-04 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| WO2007089667A1 (en) * | 2006-01-30 | 2007-08-09 | Irm Llc | Compounds and compositions as ppar modulators |
| EP2322529B1 (en) | 2006-08-31 | 2017-12-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| CN101595111A (zh) * | 2006-08-31 | 2009-12-02 | 西蒙·弗雷瑟大学 | 选择性糖苷酶抑制剂及其用途 |
| WO2011140640A1 (en) | 2010-05-11 | 2011-11-17 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2012061927A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| WO2012061972A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| LT2655388T (lt) | 2010-12-23 | 2016-11-10 | Alectos Therapeutics Inc. | Selektyvieji glikozidazės inhibitoriai ir jų panaudojimas |
| SG2014009617A (en) * | 2011-08-25 | 2014-05-29 | Merck Patent Gmbh | Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors |
-
2012
- 2012-08-22 SG SG2014009617A patent/SG2014009617A/en unknown
- 2012-08-22 KR KR1020147002525A patent/KR102008032B1/ko active Active
- 2012-08-22 AU AU2012298949A patent/AU2012298949B2/en active Active
- 2012-08-22 HU HUE12753341A patent/HUE029390T2/en unknown
- 2012-08-22 BR BR112014004219-5A patent/BR112014004219B1/pt active IP Right Grant
- 2012-08-22 RS RS20160280A patent/RS54773B1/sr unknown
- 2012-08-22 EA EA201490493A patent/EA022562B1/ru not_active IP Right Cessation
- 2012-08-22 HR HRP20160334TT patent/HRP20160334T1/hr unknown
- 2012-08-22 EP EP12753341.2A patent/EP2748171B1/en active Active
- 2012-08-22 WO PCT/US2012/051785 patent/WO2013028715A1/en not_active Ceased
- 2012-08-22 ES ES12753341.2T patent/ES2568603T3/es active Active
- 2012-08-22 DK DK12753341.2T patent/DK2748171T3/en active
- 2012-08-22 JP JP2014527246A patent/JP5893738B2/ja active Active
- 2012-08-22 PL PL12753341T patent/PL2748171T3/pl unknown
- 2012-08-22 CN CN201280041109.9A patent/CN103930428B/zh active Active
- 2012-08-22 CA CA2845149A patent/CA2845149C/en active Active
- 2012-08-22 SI SI201230534A patent/SI2748171T1/sl unknown
- 2012-08-22 US US14/131,471 patent/US8884023B2/en active Active
- 2012-08-22 MX MX2014002031A patent/MX358463B/es active IP Right Grant
-
2014
- 2014-01-17 ZA ZA2014/00387A patent/ZA201400387B/en unknown
- 2014-02-17 IL IL231008A patent/IL231008A/en active IP Right Grant
- 2014-09-30 US US14/502,213 patent/US9469657B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5893738B2 (ja) | グリコシダーゼ阻害剤としてのピラノ[3,2−d][1,3]チアゾール | |
| JP7082446B2 (ja) | スルホキシイミングリコシダーゼ阻害剤 | |
| AU2015308437B2 (en) | Glycosidase inhibitors | |
| US10995090B2 (en) | Substituted dihydrobenzofuran glycosidase inhibitors | |
| WO2020039028A1 (en) | Tetrahydro-benzoazepine glycosidase inhibitors | |
| WO2018153507A1 (en) | Substituted dihydrobenzofuran glycosidase inhibitors | |
| WO2020169804A1 (en) | Fused glycosidase inhibitors | |
| WO2019037860A1 (en) | LINEAR INHIBITORS OF GLYCOSIDASE | |
| EP3672958B1 (en) | Annulated glycosidase inhibitors | |
| HK1196607B (en) | Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors | |
| EA043636B1 (ru) | АНТИБАКТЕРИАЛЬНЫЕ 3,4-ДИГИДРО-1Н-[1,8]НАФТИРИДИНОНЫ, ЗАМЕЩЕННЫЕ ЦИКЛОПЕНТА[с]ПИРРОЛОМ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150824 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150824 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150826 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20150826 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20150916 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151002 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160104 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160125 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160224 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5893738 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |